通过增加高密度脂蛋白-胆固醇(HDL-C)和HDL功能的水平,服用Policosanol与治疗血压和血脂异常有关。虽然补充多角烷醇也改善了动物模型的肝功能,在人类临床研究中没有报道过,特别是服用20毫克剂量的多酚醇。在目前的研究中,古巴policosanol(Raydel®)的十二周消费显着增强肝功能,显示肝酶显著下降,血尿素氮,和糖化血红蛋白.从日本参与者的人体试验中,policosanol组(n=26,男性13/女性13)显示丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)从基线显着下降21%(p=0.041)和8.7%(p=0.017),分别。相比之下,安慰剂组(n=26,男13/女13)几乎无变化或轻度升高.policosanol组显示在第12周γ-谷氨酰转移酶(γ-GTP)从基线下降16%(p=0.015),而安慰剂组增加了1.2%。policosanol组在第8周显著降低血清碱性磷酸酶(ALP)水平(p=0.012),第12周(p=0.012),4周后(p=0.006)与安慰剂组相比。经过12周的多酚醇消费,血清中三价铁离子还原能力和对氧磷酶比第0周分别升高37%(p<0.001)和29%(p=0.004),而安慰剂用量无明显变化。有趣的是,糖化血红蛋白(HbA1c)在血清中显著降低在多酚醇组4周后食用,比安慰剂组低约2.1%(p=0.004)。此外,血尿素氮(BUN)和尿酸水平在4周后显著降低:比安慰剂组低14%(p=0.002)和4%(p=0.048),分别。方差分析的重复测量表明,policosanol组的AST显着降低(p=0.041),ALT(p=0.008),γ-GTP(p=0.016),ALP(p=0.003),HbA1c(p=0.010),BUN(p=0.030),和SBP(p=0.011)来自安慰剂组的时间点和组相互作用的变化。总之,12周的20毫克的多酚醇消耗显著增强肝保护通过降低血清AST,ALT,ALP,和γ-GTP通过糖化血红蛋白的减少,尿酸,和BUN,血清抗氧化能力提高。这些结果表明,通过消耗20mg的多酚醇(Raydel®)改善血压伴随着肝功能的保护和肾功能的增强。
Policosanol consumption has been associated with treating blood pressure and dyslipidemia by increasing the level of high-density lipoproteins-cholesterol (HDL-C) and HDL functionality. Although policosanol supplementation also ameliorated liver function in animal models, it has not been reported in a human clinical
study, particularly with a 20 mg doage of policosanol. In the current
study, twelve-week consumption of Cuban policosanol (Raydel®) significantly enhanced the hepatic functions, showing remarkable decreases in hepatic enzymes, blood urea nitrogen, and glycated hemoglobin. From the human
trial with Japanese participants, the policosanol group (n = 26, male 13/female 13) showed a remarkable decrease in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) from baseline up to 21% (p = 0.041) and 8.7% (p = 0.017), respectively. In contrast, the placebo group (n = 26, male 13/female 13) showed almost no change or slight elevation. The policosanol group showed a 16% decrease in γ-glutamyl transferase (γ-GTP) at week 12 from the baseline (p = 0.015), while the placebo group showed a 1.2% increase. The policosanol group exhibited significantly lower serum alkaline phosphatase (ALP) levels at week 8 (p = 0.012), week 12 (p = 0.012), and after 4-weeks (p = 0.006) compared to those of the placebo group. After 12 weeks of policosanol consumption, the ferric ion reduction ability and paraoxonase of serum were elevated by 37% (p < 0.001) and 29% (p = 0.004) higher than week 0, while placebo consumption showed no notable changes. Interestingly, glycated hemoglobin (HbA1c) in serum was lowered significantly in the policosanol group 4 weeks after consumption, which was approximately 2.1% (p = 0.004) lower than the placebo group. In addition, blood urea nitrogen (BUN) and uric acid levels were significantly lower in the policosanol group after 4 weeks: 14% lower (p = 0.002) and 4% lower (p = 0.048) than those of the placebo group, respectively. Repeated measures of ANOVA showed that the policosanol group had remarkable decreases in AST (p = 0.041), ALT (p = 0.008), γ-GTP (p = 0.016), ALP (p = 0.003), HbA1c (p = 0.010), BUN (p = 0.030), and SBP (p = 0.011) from the changes in the placebo group in point of time and group interaction. In conclusion, 12 weeks of 20 mg consumption of policosanol significantly enhanced hepatic protection by lowering the serum AST, ALT, ALP, and γ-GTP via a decrease in glycated hemoglobin, uric acid, and BUN with an elevation of serum antioxidant abilities. These results suggest that improvements in blood pressure by consumption of 20 mg of policosanol (Raydel®) were accompanied by protection of liver function and enhanced kidney function.